1 completed, 1 not yet recruiting, 1 unknown. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 1, Not yet recruiting 1, Unknown 1 |
Follow flumatinib: new trials by email Literature Review of flumatinib trials Research Report on flumatinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of HS-10382 Versus Investigator-selected TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP HS-10382, Imatinib, Dasatinib - Chronic Myeloid Leukemia | Phase 3 | Not yet recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 408 | 2026-12-01 | 2026-10-21 |
| Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALL Flumatinib - Acute Lymphocytic Leukemia, Adult B-Cell, BCR-ABL1 Fusion Protein Expression | Phase 3 | Unknown | Zhongda Hospital | 28 | 2020-03-01 | 2022-03-24 |
| The Study of the Efficacy and the Safety of Flumatinib vs Imatinib as First Line Treatment in Patients With CML Flumatinib 600mg qd, Imatinib 400mg qd - CML, CML-CP,MMR,TKI | Phase 3 | Completed | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 400 | 2014-06-01 | 2018-02-27 |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Neoplasm, Residual (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Jiangsu Hansoh Pharmaceutical Co., Ltd. (2) · Zhongda Hospital (1)
China (3)